Biological actions of curcumin on articular chondrocytes

Osteoarthritis and Cartilage

Volumn 18, Issue 2, 2010, Pages 141-149

  Henrotin, Y ^a   Clutterbuck, A L ^b   Allaway, D ^c   Lodwig, E M ^c   Harris, P ^c   Mathy Hartert, M ^a   Shakibaei, M ^d   Mobasheri, A ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c WALTHAM CENTRE FOR PET NUTRITION   (United Kingdom)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Apoptosis; Articular cartilage; Curcumin; Cytotoxicity; Inflammation; Inflammatory mediator; Nuclear factor kappa B (NF B) cell signalling; Osteoarthritis (OA); Pro inflammatory cytokine

Indexed keywords

ARACHIDONIC ACID; BETA1 INTEGRIN; CASPASE 3; COLLAGEN TYPE 2; COLLAGENASE 3; CURCUMIN; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; LIPOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE 12; PHOSPHOLIPASE A2; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROTEIN C JUN; STROMELYSIN;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CARTILAGE CELL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME ACTIVATION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDLINE; OSTEOARTHRITIS; OSTEOBLAST; PRIORITY JOURNAL; PROTEOGLYCAN SYNTHESIS; REVIEW;

ANTIGENS, CD18; APOPTOSIS; CARTILAGE, ARTICULAR; CASPASE 3; CELLS, CULTURED; CHONDROCYTES; COLLAGEN TYPE II; CURCUMIN; ENZYME INHIBITORS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MATRIX METALLOPROTEINASE 3; NF-KAPPA B; OSTEOARTHRITIS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

EID: 74349120817     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2009.10.002     Document Type: Review

References (65)

1. Srimal R.C., and Dhawan B.N. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 25 (1973) 447-452
2. Goel A., Kunnumakkara A.B., and Aggarwal B.B. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 75 (2008) 787-809
3. Nikitin A., Egorov S., Daraselia N., and Mazo I. Pathway studio-the analysis and navigation of molecular networks. Bioinformatics 19 (2003) 2155-2157
4. Srivastava R., and Srimal R.C. Modification of certain inflammation-induced biochemical changes by curcumin. Indian J Med Res 81 (1985) 215-223
5. Mukhopadhyay A., Basu N., Ghatak N., and Gujral P.K. Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Actions 12 (1982) 508-515
6. Asakawa N., Tsuno M., Hattori T., Ueyama M., Shinoda A., Miyake Y., et al. Determination of curcumin content of turmeric by high performance liquid chromatography. (author's transl). Yakugaku Zasshi 101 (1981) 374-377
7. Zeng Y., Qiu F., Liu Y., Qu G., and Yao X. Isolation and identification of phase 1 metabolites of demethoxycurcumin in rats. Drug Metab Dispos 35 (2007) 1564-1573
8. Payton F., Sandusky P., and Alworth W.L. NMR study of the solution structure of curcumin. J Nat Prod 70 (2007) 143-146
9. Sharma R.A., Gescher A.J., and Steward W.P. Curcumin: the story so far. Eur J Cancer 41 (2005) 1955-1968
10. Ireson C.R., Jones D.J., Orr S., Coughtrie M.W., Boocock D.J., Williams M.L., et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 11 (2002) 105-111
11. Ireson C., Orr S., Jones D.J., Verschoyle R., Lim C.K., Luo J.L., et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61 (2001) 1058-1064
12. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21 (2001) 2895-2900
13. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10 (2004) 6847-6854
14. Heath D.D., Pruitt M.A., Brenner D.E., Begum A.N., Frautschy S.A., and Rock C.L. Tetrahydrocurcumin in plasma and urine: quantitation by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 824 (2005) 206-212
15. Garcea G., Berry D.P., Jones D.J., Singh R., Dennison A.R., Farmer P.B., et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14 (2005) 120-125
16. Garcea G., Jones D.J., Singh R., Dennison A.R., Farmer P.B., Sharma R.A., et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90 (2004) 1011-1015
17. Anand P., Kunnumakkara A.B., Newman R.A., and Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 4 (2007) 807-818
18. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., and Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64 (1998) 353-356
19. Li L., Braiteh F.S., and Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104 (2005) 1322-1331
20. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., Maitra A., et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology 5 (2007) 3
21. Maiti K., Mukherjee K., Gantait A., Saha B.P., and Mukherjee P.K. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 330 (2007) 155-163
22. Cui J., Yu B., Zhao Y., Zhu W., Li H., Lou H., et al. Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm 371 (2009) 148-155
23. Tomren M.A., Masson M., Loftsson T., and Tonnesen H.H. Studies on curcumin and curcuminoids XXXI. Symmetric and asymmetric curcuminoids: stability, activity and complexation with cyclodextrin. Int J Pharm 338 (2007) 27-34
24. Anuchapreeda S., Leechanachai P., Smith M.M., Ambudkar S.V., and Limtrakul P.N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64 (2002) 573-582
25. Gopinath D., Ahmed M.R., Gomathi K., Chitra K., Sehgal P.K., and Jayakumar R. Dermal wound healing processes with curcumin incorporated collagen films. Biomaterials 25 (2004) 1911-1917
26. Chan M.M., Huang H.I., Fenton M.R., and Fong D. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 55 (1998) 1955-1962
27. Wang Y.J., Pan M.H., Cheng A.L., Lin L.I., Ho Y.S., Hsieh C.Y., et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 15 (1997) 1867-1876
28. Kurien B.T., Singh A., Matsumoto H., and Scofield R.H. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol 5 (2007) 567-576
29. Tonnesen H.H., Masson M., and Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm 244 (2002) 127-135
30. Jackson J.K., Higo T., Hunter W.L., and Burt H.M. The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflamm Res 55 (2006) 168-175
31. Thompson K.H., Bohmerle K., Polishchuk E., Martins C., Toleikis P., Tse J., et al. Complementary inhibition of synoviocyte, smooth muscle cell or mouse lymphoma cell proliferation by a vanadyl curcumin complex compared to curcumin alone. J Inorg Biochem 98 (2004) 2063-2070
32. Lev-Ari S., Strier L., Kazanov D., Elkayam O., Lichtenberg D., Caspi D., et al. Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. Rheumatology (Oxford) 45 (2006) 171-177
33. Toegel S., Wu S.Q., Piana C., Unger F.M., Wirth M., Goldring M.B., et al. Comparison between chondroprotective effects of glucosamine, curcumin, and diacerein in IL-1beta-stimulated C-28/I2 chondrocytes. Osteoarthritis Cartilage 16 (2008) 1205-1212
34. Shakibaei M., Schulze-Tanzil G., John T., and Mobasheri A. Curcumin protects human chondrocytes from IL-l1beta-induced inhibition of collagen type II and beta1-integrin expression and activation of caspase-3: an immunomorphological study. Ann Anat 187 (2005) 487-497
35. Henrotin Y., and Kurz B. Antioxidant to treat osteoarthritis: dream or reality?. Curr Drug Targets 8 (2007) 347-357
36. Abramson S.B. Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res Ther 10 Suppl 2 (2008) S2
37. Henrotin Y.E., Bruckner P., and Pujol J.P. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 11 (2003) 747-755
38. Henrotin Y., Kurz B., and Aigner T. Oxygen and reactive oxygen species in cartilage degradation: friends or foes?. Osteoarthritis Cartilage 13 (2005) 643-654
39. Henrotin Y., Sanchez C., and Balligand M. Pharmaceutical and nutraceutical management of canine osteoarthritis: present and future perspectives. Vet J 170 (2005) 113-123
40. Sreejayan, and Rao M.N. Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol 49 (1997) 105-107
41. Sreejayan N., and Rao M.N. Free radical scavenging activity of curcuminoids. Arzneimittelforschung 46 (1996) 169-171
42. Swarnakar S., Ganguly K., Kundu P., Banerjee A., Maity P., and Sharma A.V. Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacin-induced gastric ulcer. J Biol Chem 280 (2005) 9409-9415
43. Nishinaka T., Ichijo Y., Ito M., Kimura M., Katsuyama M., Iwata K., et al. Curcumin activates human glutathione S-transferase P1 expression through antioxidant response element. Toxicol Lett 170 (2007) 238-247
44. Hong J., Bose M., Ju J., Ryu J.H., Chen X., Sang S., et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25 (2004) 1671-1679
45. Schulze-Tanzil G., Mobasheri A., Sendzik J., John T., and Shakibaei M. Effects of curcumin (diferuloylmethane) on nuclear factor kappaB signaling in interleukin-1beta-stimulated chondrocytes. Ann N Y Acad Sci 1030 (2004) 578-586
46. Brouet I., and Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 206 (1995) 533-540
47. Nanji A.A., Jokelainen K., Tipoe G.L., Rahemtulla A., Thomas P., and Dannenberg A.J. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. Am J Physiol Gastrointest Liver Physiol 284 (2003) G321-G327
48. Onodera S., Kaneda K., Mizue Y., Koyama Y., Fujinaga M., and Nishihira J. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem 275 (2000) 444-450
49. Liacini A., Sylvester J., Li W.Q., and Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 21 (2002) 251-262
50. Li W.Q., Dehnade F., and Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 166 (2001) 3491-3498
51. Berenbaum F. Signaling transduction: target in osteoarthritis. Curr Opin Rheumatol 16 (2004) 616-622
52. Gilmore T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25 (2006) 6680-6684
53. Hess J., Angel P., and Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117 (2004) 5965-5973
54. Glover J.N., and Harrison S.C. Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA. Nature 373 (1995) 257-261
55. Roman-Blas J.A., and Jimenez S.A. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 14 (2006) 839-848
56. Roshak A.K., Callahan J.F., and Blake S.M. Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease. Curr Opin Pharmacol 2 (2002) 316-321
57. Huang T.S., Lee S.C., and Lin J.K. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA 88 (1991) 5292-5296
58. Onodera S., Nishihira J., Iwabuchi K., Koyama Y., Yoshida K., Tanaka S., et al. Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J Biol Chem 277 (2002) 7865-7874
59. Liacini A., Sylvester J., Li W.Q., Huang W., Dehnade F., Ahmad M., et al. Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res 288 (2003) 208-217
60. Kawasaki H., Komai K., Nakamura M., Yamamoto E., Ouyang Z., Nakashima T., et al. Human wee1 kinase is directly transactivated by and increased in association with c-Fos/AP-1: rheumatoid synovial cells overexpressing these genes go into aberrant mitosis. Oncogene 22 (2003) 6839-6844
61. Lin S.K., Kok S.H., Yeh F.T., Kuo M.Y., Lin C.C., Wang C.C., et al. MEK/ERK and signal transducer and activator of transcription signaling pathways modulate oncostatin M-stimulated CCL2 expression in human osteoblasts through a common transcription factor. Arthritis Rheum 50 (2004) 785-793
62. Sylvester J., Liacini A., Li W.Q., and Zafarullah M. Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3, -13 and aggrecanase-1 genes in articular chondrocytes. Cell Signal 16 (2004) 469-476
63. Cho M.L., Jung Y.O., Moon Y.M., Min S.Y., Yoon C.H., Lee S.H., et al. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett 103 (2006) 159-166
64. Shakibaei M., John T., Schulze-Tanzil G., Lehmann I., and Mobasheri A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol 73 (2007) 1434-1445
65. Hettne K.M., de Mos M., de Bruijn A.G., Weeber M., Boyer S., van Mulligen E.M., et al. Applied information retrieval and multidisciplinary research: new mechanistic hypotheses in complex regional pain syndrome. J Biomed Discov Collab 2 (2007) 2